Betamethasone valerate foam is indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the scalp.
The Guidance would support biologic drug competition, increase patient access to biosimilars and lower healthcare costs for patients, the FTC’s comment says.